BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionAssetmark, Inc
Latest Disclosed Ownership20,790 shares
Latest Disclosed Value $ 1,543,865
Assetmark, Inc reports 423.68% increase in ownership of BBIO / BridgeBio Pharma, Inc.

On May 6, 2026 - Assetmark, Inc filed a 13F-HR form disclosing ownership of 20,790 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $1,543,865 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 3,970 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 423.68% during the quarter. The current value of the position is $1,361,329 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 20,790 16,820 423.68 1,544 409.24 0.0031
2026-01-23 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 3,970 -448 -10.14 304 32.31 0.0006
2025-11-06 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 4,418 1,608 57.22 229 89.26 0.0005
2025-08-04 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 2,810 -52 -1.82 121 23.47 0.0003
2025-05-06 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,862 -112 -3.77 99 20.99 0.0003
2025-02-06 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,974 -444 -12.99 82 -6.90 0.0002
2024-11-01 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 3,418 156 4.78 87 6.10 0.0002
2024-08-13 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 3,262 433 15.31 83 -5.75 0.0003
2024-05-07 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,829 -102 -3.48 87 -26.27 0.0003
2024-02-09 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 2,931 935 46.84 118 126.92 0.0004
2023-10-27 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,996 1,996 53 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.